teprotumumab
Sign in to saveAlso known as R1507
Teprotumumab, sold under the brand name Tepezza, is a medication used to treat thyroid eye disease (Graves' eye disease), a rare condition where the muscles and fatty tissues behind the eye become inflamed, causing the eyes to bulge outwards. It is a human monoclonal antibody developed by Genmab and Roche for tumor treatment but was later developed by River Vision Development Corporation and Horizon Therapeutics to be used for ophthalmic uses. It binds to IGF-1R.
Research
437 papers- Teprotumumab for the Treatment of Active Thyroid Eye Disease.The New England journal of medicine · 2020
- Teprotumumab.2006
- Teprotumumab: A Review in Thyroid Eye Disease.Drugs · 2022
- Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment: OPTIC-X Study.Ophthalmology · 2022
- Teprotumumab.2012
via PubMed
~4 min read
Encyclopedic overview
5 sectionsContents
- Medical use
- History
- Society and culture
- Legal status
- References
Teprotumumab, sold under the brand name Tepezza, is a medication used to treat thyroid eye disease (Graves' eye disease), a rare condition where the muscles and fatty tissues behind the eye become inflamed, causing the eyes to bulge outwards. It is a human monoclonal antibody developed by Genmab and Roche for tumor treatment but was later developed by River Vision Development Corporation and Horizon Therapeutics to be used for ophthalmic uses. It binds to IGF-1R.
The most common side effects are muscle spasm, nausea, hair loss, diarrhea, fatigue, high blood sugar, hearing loss, dry skin, altered sense of taste, and headache. Teprotumumab should not be used if pregnant.
Excerpted from Wikipedia’s “teprotumumab” article, available under the CC BY-SA 4.0 licence.